Matthew Segar
Internal Medicine · Houston, TXNPI 1942703749
Payments from drug & device makers
Across 401 payments — averaging $117.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18K
- Medtronic$10K
- Idorsia Pharmaceuticals US Inc$7K
- Biosense Webster, Inc.$3K
- Boston Scientific$2K
- Abbott$1K
- plus $6K from 35 others
Across 6 payments — averaging $816.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
What the payments were for
- Speaking & faculty fees$16,13534%
- Grants$4,50010%
- Travel & lodging$13,04828%
- Food & beverage$11,97725%
- Education$1,5753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$9,438
- Tryvio$6,796
- Carto 3$2,154
- SAMSCA$1,050
- WATCHMAN Access System$1,016
- OPTIMIZER$443
- FLOWTRIEVER CATHETER, S$223
- ENSITE$212
- WATCHMAN FLX$164
- Micra$161
- NA$146
- AVEIR$144
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$128
- Watchman$111
How this compares
$47,236 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $11,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $363 | $11,47820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.